

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SoftMedx Healthcare Limited

京玖醫療健康有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 648)

ANNOUNCEMENT

Reference is made to the annual report of SoftMedx Healthcare Limited (the “Company”) for the year ended 31 December 2022. The Company would like to clarify that the audit opinion of its auditors rendered for the Company’s consolidated financial statements for the year ended 31 December 2022 was not modified in respect of the matters described in the paragraph headed “material uncertainty relating to going concern” in the said annual report.

Trading in the shares of the Company will continue to be suspended pending fulfilment of the resumption conditions. The Company will keep its shareholders and potential investors posted of any material development in this regard as and when appropriate.

Shareholders and potential investors of the Company should exercise caution when dealing in the shares of the Company.

For and on behalf of the board of
SoftMedx Healthcare Limited
Lam Sung Him Gaston
Company Secretary

Hong Kong, 6 November 2023

As at the date of this announcement, the board of directors of the Company comprises Mr. Cheung Wai Kwan and Mr. Wang Jianguo as executive directors; and Ms. Hu Xuezheng, Mr. Lin Pinzhao and Mr. Yiu Chun Wing as independent non-executive directors.